IN2014MN01493A - - Google Patents

Info

Publication number: IN2014MN01493A
Authority: IN; India
Prior art keywords: oligonucleotides; modulating; present; gene; tumoural
Prior art date: 2012-02-24

Application number

Other languages

English (en)

Inventor

Roberto Tonelli

Leonardo Venturelli

Andrea Tortori

Luca Montemurro

Original Assignee

Biogenera S P A

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-02-24

Filing date

2013-02-21

Publication date

2015-04-17

2013-02-21 Application filed by Biogenera S P A filed Critical Biogenera S P A

2015-04-17 Publication of IN2014MN01493A publication Critical patent/IN2014MN01493A/en

Links

108091034117 Oligonucleotide Proteins 0.000 abstract 2
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 2
108090000623 proteins and genes Proteins 0.000 abstract 2
238000003745 diagnosis Methods 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000002068 genetic effect Effects 0.000 abstract 1
230000007170 pathology Effects 0.000 abstract 1
230000003612 virological effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3181—Peptide nucleic acid, PNA
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Genetics & Genomics (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Oncology (AREA)
Neurology (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Inorganic Chemistry (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Neurosurgery (AREA)
Heart & Thoracic Surgery (AREA)
Gastroenterology & Hepatology (AREA)
Hematology (AREA)
Ophthalmology & Optometry (AREA)
Virology (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)

IN1493MUN2014 2012-02-24 2013-02-21 IN2014MN01493A (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IT000275A ITMI20120275A1 (it)	2012-02-24	2012-02-24	Oligonucleotidi per la modulazione dell'espressione genica e loro usi
PCT/IB2013/051410 WO2013124807A2 (en)	2012-02-24	2013-02-21	Oligonucleotides for modulating gene expression and uses thereof

Publications (1)

Publication Number	Publication Date
IN2014MN01493A true IN2014MN01493A (de)	2015-04-17

Family

ID=45999941

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IN1493MUN2014 IN2014MN01493A (de)	2012-02-24	2013-02-21

Country Status (28)

Country	Link
US (2)	US10023867B2 (de)
EP (1)	EP2817407B1 (de)
JP (2)	JP6333739B2 (de)
KR (1)	KR101992925B1 (de)
CN (2)	CN104169421A (de)
AR (1)	AR090129A1 (de)
AU (2)	AU2013223694B2 (de)
BR (1)	BR112014020885B1 (de)
CA (1)	CA2864060C (de)
CY (1)	CY1120084T1 (de)
DK (1)	DK2817407T3 (de)
ES (1)	ES2651147T3 (de)
HK (1)	HK1201878A1 (de)
HU (1)	HUE034846T2 (de)
IN (1)	IN2014MN01493A (de)
IT (1)	ITMI20120275A1 (de)
LT (1)	LT2817407T (de)
MA (1)	MA35935B1 (de)
NO (1)	NO2817407T3 (de)
PL (1)	PL2817407T3 (de)
PT (1)	PT2817407T (de)
RS (1)	RS56631B1 (de)
RU (1)	RU2648140C2 (de)
SG (2)	SG10201606946YA (de)
SI (1)	SI2817407T1 (de)
SM (1)	SMT201800042T1 (de)
TN (1)	TN2014000327A1 (de)
WO (1)	WO2013124807A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ITMI20120275A1 (it) *	2012-02-24	2013-08-25	Biogenera Societa A Responsabilita Limitata	Oligonucleotidi per la modulazione dell'espressione genica e loro usi
US10837014B2 (en)	2012-05-16	2020-11-17	Translate Bio Ma, Inc.	Compositions and methods for modulating SMN gene family expression
EA201492116A1 (ru)	2012-05-16	2015-05-29	Рана Терапьютикс, Инк.	Композиции и способы для модулирования экспрессии mecp2
HK1208700A1 (en)	2012-05-16	2016-03-11	Rana Therapeutics Inc.	Compositions and methods for modulating smn gene family expression
EP2850188A4 (de)	2012-05-16	2016-01-20	Rana Therapeutics Inc	Zusammensetzungen und verfahren zur modulierung der expression der hämoglobin-genfamilien
CA2873797A1 (en)	2012-05-16	2013-11-21	Rana Therapeutics Inc.	Compositions and methods for modulating utrn expression
BR112014028644A2 (pt)	2012-05-16	2017-08-15	Rana Therapeutics Inc	Composições e métodos para modulação da expressão de atp2a2
MX2019006803A (es)	2016-12-13	2019-11-18	Am Sciences Inc	Composicion farmaceutica para prevenir o tratar la hepatitis b.

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1999009045A1 (en) *	1997-08-20	1999-02-25	Somagenics, Inc.	Antisense and antigene therapeutics with improved binding properties and methods for their use
WO2001061030A2 (en) *	2000-02-14	2001-08-23	Bollon Arthur P	LIBRARIES OF OPTIMUM SUBSEQUENCE REGIONS OF mRNA AND GENOMIC DNA FOR CONTROL OF GENE EXPRESSION
JP2004524371A (ja) *	2001-04-13	2004-08-12	ザ・ポピュレイション・カウンシル，インコーポレイテッド	核レセプターを介するペプチド核酸の細胞核内導入
WO2002092617A1 (en)	2001-05-17	2002-11-21	Avi Biopharma, Inc.	Combined approach to treatment of cancer using a c-myc antisense oligomer
EP1448590A4 (de) *	2002-02-20	2004-12-15	Sirna Therapeutics Inc	Durch rna-interferenz vermittelte hemmung der myc und myb-gene oder gene der entsprechenden synthesewege
ITMI20030860A1 (it) *	2003-04-29	2004-10-30	Univ Bologna	Metodo per l'inibizione selettiva del gene n-myc
WO2005045032A2 (en)	2003-10-20	2005-05-19	Sima Therapeutics, Inc.	RNA INTERFERENCE MEDIATED INHIBITION OF EARLY GROWTH RESPONSE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
GB0415263D0 (en) *	2004-07-07	2004-08-11	Norwegian Radium Hospital Res	Method
BRPI0517021A (pt) *	2004-10-25	2008-09-30	Novartis Ag	polinucleotìdeos e polipeptìdeos de torc, e métodos de uso
US20090324587A1 (en) *	2005-12-01	2009-12-31	Neal Clifford Goodwin	Cancer Therapies and Pharmaceutical Compositions Used Therein
US7625874B2 (en) *	2006-04-11	2009-12-01	The Regents Of The University Of California	Compositions and methods for treating diseases associated with T-box and N-Myc
US20080038783A1 (en) *	2006-06-29	2008-02-14	Applera Corporation	Compositions and Methods Pertaining to Guanylation of PNA Oligomers
WO2009009739A2 (en) *	2007-07-12	2009-01-15	Theracrine, Inc.	Methods and compositions for facilitating cell death of cancer stem cells and for treating cancer
EP2268284A2 (de) *	2008-02-05	2011-01-05	Antisoma Research Limited	Verwendung von g-reichen oligonucleotiden zur behandlung von neoplastischen erkrankungen
EP2370582B1 (de) *	2008-12-04	2017-05-10	CuRNA, Inc.	Behandlung von tumorsuppressorgen-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen das gen
CN102058535B (zh) *	2010-12-21	2013-05-01	中国人民解放军总医院	叶酸受体靶向的新型脂质体
ITMI20120275A1 (it) *	2012-02-24	2013-08-25	Biogenera Societa A Responsabilita Limitata	Oligonucleotidi per la modulazione dell'espressione genica e loro usi

2012
- 2012-02-24 IT IT000275A patent/ITMI20120275A1/it unknown
2013
- 2013-02-21 CA CA2864060A patent/CA2864060C/en active Active
- 2013-02-21 SI SI201330845T patent/SI2817407T1/en unknown
- 2013-02-21 PT PT137164158T patent/PT2817407T/pt unknown
- 2013-02-21 JP JP2014558247A patent/JP6333739B2/ja active Active
- 2013-02-21 AU AU2013223694A patent/AU2013223694B2/en active Active
- 2013-02-21 SM SM20180042T patent/SMT201800042T1/it unknown
- 2013-02-21 CN CN201380009360.1A patent/CN104169421A/zh active Pending
- 2013-02-21 US US14/379,729 patent/US10023867B2/en active Active
- 2013-02-21 KR KR1020147026837A patent/KR101992925B1/ko active Active
- 2013-02-21 BR BR112014020885-9A patent/BR112014020885B1/pt active IP Right Grant
- 2013-02-21 RU RU2014138198A patent/RU2648140C2/ru active
- 2013-02-21 PL PL13716415T patent/PL2817407T3/pl unknown
- 2013-02-21 IN IN1493MUN2014 patent/IN2014MN01493A/en unknown
- 2013-02-21 CN CN202210708144.7A patent/CN115216475A/zh active Pending
- 2013-02-21 WO PCT/IB2013/051410 patent/WO2013124807A2/en active Application Filing
- 2013-02-21 SG SG10201606946YA patent/SG10201606946YA/en unknown
- 2013-02-21 ES ES13716415.8T patent/ES2651147T3/es active Active
- 2013-02-21 HK HK15102407.6A patent/HK1201878A1/xx unknown
- 2013-02-21 HU HUE13716415A patent/HUE034846T2/en unknown
- 2013-02-21 RS RS20171253A patent/RS56631B1/sr unknown
- 2013-02-21 DK DK13716415.8T patent/DK2817407T3/en active
- 2013-02-21 EP EP13716415.8A patent/EP2817407B1/de active Active
- 2013-02-21 LT LTEP13716415.8T patent/LT2817407T/lt unknown
- 2013-02-21 SG SG11201404852WA patent/SG11201404852WA/en unknown
- 2013-02-21 NO NO13716415A patent/NO2817407T3/no unknown
- 2013-02-22 AR ARP130100546A patent/AR090129A1/es active IP Right Grant
2014
- 2014-07-31 TN TNP2014000327A patent/TN2014000327A1/fr unknown
- 2014-09-10 MA MA37342A patent/MA35935B1/fr unknown
2017
- 2017-12-05 CY CY20171101270T patent/CY1120084T1/el unknown
- 2017-12-12 JP JP2017237889A patent/JP2018078893A/ja active Pending
2018
- 2018-06-15 US US16/009,303 patent/US10752900B2/en active Active
- 2018-12-13 AU AU2018278972A patent/AU2018278972A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AR090129A1 (es)	2014-10-22
DK2817407T3 (en)	2017-12-18
SI2817407T1 (en)	2018-01-31
ITMI20120275A1 (it)	2013-08-25
US10752900B2 (en)	2020-08-25
HUE034846T2 (en)	2018-03-28
JP2015513398A (ja)	2015-05-14
ES2651147T3 (es)	2018-01-24
CN104169421A (zh)	2014-11-26
PT2817407T (pt)	2017-12-07
US20160040166A1 (en)	2016-02-11
TN2014000327A1 (en)	2015-12-21
BR112014020885B1 (pt)	2020-10-27
WO2013124807A2 (en)	2013-08-29
AU2018278972A1 (en)	2019-01-17
JP2018078893A (ja)	2018-05-24
EP2817407B1 (de)	2017-09-06
MA35935B1 (fr)	2014-12-01
LT2817407T (lt)	2018-01-25
SMT201800042T1 (it)	2018-03-08
HK1201878A1 (en)	2015-09-11
CA2864060A1 (en)	2013-08-29
RU2648140C2 (ru)	2018-03-22
WO2013124807A3 (en)	2013-12-27
BR112014020885A2 (pt)	2018-01-09
CA2864060C (en)	2020-03-10
SG10201606946YA (en)	2016-10-28
PL2817407T3 (pl)	2018-03-30
CN115216475A (zh)	2022-10-21
NO2817407T3 (de)	2018-02-03
KR20140130514A (ko)	2014-11-10
RU2014138198A (ru)	2016-04-10
RS56631B1 (sr)	2018-03-30
AU2013223694A1 (en)	2014-09-25
SG11201404852WA (en)	2014-10-30
EP2817407A2 (de)	2014-12-31
KR101992925B1 (ko)	2019-06-25
US20180282731A1 (en)	2018-10-04
CY1120084T1 (el)	2018-12-12
AU2013223694B2 (en)	2019-01-03
US10023867B2 (en)	2018-07-17
JP6333739B2 (ja)	2018-05-30

Publication	Publication Date	Title
PH12019502292A1 (en)	2021-03-15	Methods and compositions for treatment of a genetic condition
IN2014MN01493A (de)	2015-04-17
MX356525B (es)	2018-06-01	Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia.
MX2012003770A (es)	2012-08-03	Metodos para la modulacion de autofagia a traves de la modulacion de productos de genes que aumentan la autofagia.
IL265774B (en)	2020-05-31	Diagnosis, prevention and treatment of joint diseases
NZ704039A (en)	2018-04-27	Cell-free dna as a therapeutic target for female infertility and diagnostic marker
PH12014501702A1 (en)	2014-10-13	Imidazopyrrolidinone compounds
WO2014055790A9 (en)	2014-06-05	Methods and processes for non-invasive assessment of genetic variations
GEP20156347B (en)	2015-08-10	Benzodioxane inhibitors of leukotriene production
MX357656B (es)	2018-07-18	Alfa-1-microglobulina para usarse en tratamiento de enfermedades relacionadas a mitocondrias.
EP2961277A4 (de)	2016-12-28	Verwendung von aus menschlichen pluripotenten stammzellen gewonnenen nervenzellen zur behandlung von neurodegenerativen erkrankungen
SG10201703677VA (en)	2017-06-29	Methods of treating s. aureus-associated diseases
EP3052191A4 (de)	2017-03-08	Gezielte differenzierung von astrozyten aus menschlichen pluripotenten stammzellen zur verwendung im drogenscreening und zur behandlung von amyotropher lateralsklerose (als)
IL239078A0 (en)	2015-07-30	Protein for use in the treatment of eye diseases
EP3135766A4 (de)	2017-12-06	Aptamer zur bindung an autotaxin und hemmung der biologischen aktivität von autotaxin sowie verwendung dafür
BR112013016878A2 (pt)	2017-07-04	dna envolvido na regulação da expressão do gene em tecido fotossintético.
HK40095805A (en)	2024-02-09	Methods and processes for non-invasive assessment of genetic variations
HK40088019A (en)	2023-09-22	Methods and processes for non-invasive assessment of genetic variations
UA61823U (ru)	2011-07-25	Применение гамма-оксимасляной кислоты как стимулятора ускорения скорости регенерации и восстановления силы мышечных сокращений